Emergent Biosolutions Inc (NYSE: EBS) is -39.33% lower on its value in year-to-date trading and has touched a low of $1.82 and a high of $15.10 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EBS stock was last observed hovering at around $6.39 in the last trading session, with the day’s loss setting it -0.59%.
Currently trading at $5.80, the stock is -30.48% and -37.64% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.78 million and changing -9.23% at the moment leaves the stock -33.48% off its SMA200. EBS registered 71.09% gain for a year compared to 6-month gain of -30.20%.
The stock witnessed a -44.71% loss in the last 1 month and extending the period to 3 months gives it a -42.69%, and is -20.22% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.51% over the week and 8.26% over the month.
Emergent Biosolutions Inc (EBS) has around 900 employees, a market worth around $314.27M and $1.04B in sales. Fwd P/E is 7.03. Profit margin for the company is -18.26%. Distance from 52-week low is 218.66% and -61.59% from its 52-week high. The company has generated returns on investments over the last 12 months (-16.49%).
with sales reaching $218.5M over the same period.The EPS is expected to grow by 598.55% this year, but quarterly earnings will post -20.95% year-over-year. Quarterly sales are estimated to shrink -27.26% in year-over-year returns.
The shares outstanding are 54.30M, and float is at 52.82M with Short Float at 13.43%.
The top institutional shareholder in the company is BLACKROCK INC. with over 3.84 million shares valued at $26.18 million. The investor’s holdings represent 7.3551 of the EBS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 3.67 million shares valued at $25.0 million to account for 7.0234 of the shares outstanding. The other top investors are CHARLES SCHWAB INVESTMENT MANAGEMENT INC which holds 3.17 million shares representing 6.0195 and valued at over $21.59 million, while MORGAN STANLEY holds 2.3796 of the shares totaling 1.24 million with a market value of $8.47 million.
Emergent Biosolutions Inc (EBS) Insider Activity
A total of 0 insider transactions have happened at Emergent Biosolutions Inc (EBS) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by DeGolyer Donald W, the company’s Director. SEC filings show that DeGolyer Donald W sold 25,000 shares of the company’s common stock on Nov 12 ’24 at a price of $10.91 per share for a total of $0.27 million. Following the sale, the insider now owns 0.11 million shares.
Emergent Biosolutions Inc disclosed in a document filed with the SEC on Nov 11 ’24 that White Marvin L (Director) sold a total of 14,287 shares of the company’s common stock. The trade occurred on Nov 11 ’24 and was made at $11.97 per share for $0.17 million. Following the transaction, the insider now directly holds 54092.0 shares of the EBS stock.
Still, SEC filings show that on Nov 12 ’24, DeGolyer Donald W (Director) Proposed Sale 25,000 shares at an average price of $11.77 for $0.29 million. The insider now directly holds shares of Emergent Biosolutions Inc (EBS).
Emergent Biosolutions Inc (EBS): Who are the competitors?
One of the company’s main competitors (and peers) include SIGA Technologies Inc. (SIGA) that is trading 8.96% up over the past 12 months.Pfizer Inc. (PFE) lies in the list of competitors of the Emergent Biosolutions Inc and is -4.60% lower over the same period from EBSSoligenix Inc. (SNGX) is -81.91% down on the 1-year trading charts.
